KAI-CHI CHANGMEI-HWEI CHANGLin L.-H.HUEY-LING CHEN2020-03-102020-03-1020190269-2813https://www.scopus.com/inward/record.uri?eid=2-s2.0-85071279666&doi=10.1111%2fapt.15404&partnerID=40&md5=dabca88c292809900f28e9d0e69efe7bhttps://scholars.lib.ntu.edu.tw/handle/123456789/475062English[SDGs]SDG3[SDGs]SDG5hepatitis B antibody; hepatitis B antigen; tenofovir disoproxil; virus DNA; tenofovir; age; cost benefit analysis; drug cost; drug safety; Editorial; follow up; hepatitis B; human; incubation time; infection prevention; practice guideline; pregnancy; priority journal; treatment indication; vaccination; vertical transmission; child; chronic hepatitis B; female; hemochromatosis; Hepatitis B virus; Macacine herpesvirus 1; mother; vertical transmission; viremia; Child; Female; Hemochromatosis; Hepatitis B virus; Hepatitis B, Chronic; Herpesvirus 1, Cercopithecine; Humans; Infectious Disease Transmission, Vertical; Mothers; Tenofovir; Viremiaeditorial10.1111/apt.15404314562992-s2.0-85071279666